ArticleJournal of ginseng research2025
Gintonin enhances epithelial barrier function by activating NRF2 pathway in radiation-induced intestinal injury.
Article in Journal of ginseng research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nrf2 as a therapeutic target of ginseng: A comprehensive review from preclinical evidence to clinical applications.Journal of ginseng research · 2026Review
- Huangqi Baihe Granules alleviate chemotherapy-induced intestinal mucositis in Drosophila and mice.AMB Express · 2026Article
- Therapeutic potential of ginseng and its bioactive compounds in inflammatory bowel disease: current evidence and future directions.Frontiers in immunology · 2026Review
- The therapeutic role of ginseng in promoting hippocampal neurogenesis and ameliorating cognitive function following whole brain radiotherapy in rats.Metabolic brain disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Because the intestine is a radio-sensitive organ in the body, and radiation-induced intestinal injury is a major clinical problem associated with radiotherapy or radiological accidents. Dysfunction of the epithelial barrier leads to bacterial translocation to other organs, resulting in severe inflammation. Recent findings suggest that gintonin (GT) suppresses oxidative stress and inflammation in neuroinflammatory diseases. Purpose: This study objected to elucidate the mitigating effects of GT on radiation-induced intestinal injury. Methods: The therapeutic effects of GT were assessed in a mouse model of radiation-induced intestinal injury using histological, immunohistochemical, and real-time PCR. Additionally, the direct effects of GT and NF-E2-related factor 2 (NRF2) activators on radiation-induced epithelial damage were assessed using Caco-2 cell monolayers. Results: GT treatment reversed radiation-induced body weight loss, attenuated intestinal damage, and inhibited inflammatory response by reducing inflammatory cell infiltration and cytokine expression in the intestines of mice. Additionally, GT treatment activated NRF2 and ameliorated intestinal barrier damage. In vitro experiments showed that GT treatment affected epithelial permeability and intercellular junction expression in Caco-2 cell monolayers under irradiated conditions. Moreover, treatment with NRF2 activator improved epithelial permeability, improved the expression of intercellular junctions in irradiated epithelial cells, and attenuated radiation-induced intestinal injury in a mouse model. Conclusion: GT maintains epithelial integrity by activating NRF2-mediated antioxidant activity in radiation-induced intestinal epithelial damage of mice. Overall, these results suggest that GT could be a novel therapeutic agent for radiation-induced intestinal damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.